Business Context and Reporting Period
Company: SeaStar Medical Holding Corp (ICU)
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2023
Reporting Period: Events occurring on August 7, 2023, relating to amendments of a Convertible Note Financing agreement entered into on March 15, 2023.
Key Financial Metrics and Capital Structure
This filing details specific financing transactions rather than periodic financial performance metrics (revenue, profit, cash flow). Key capital structure updates include:
- New Debt Issued: $543,478.26 in principal amount of senior unsecured convertible notes.
- Conversion Price: Initial conversion price of $0.20 per share for the new note.
- Warrants Issued:
- 738,791 shares via warrant attached to the new note.
- 4,765,620 shares via additional warrant issued under the Letter Agreement.
- Future Funding Commitment: Purchaser committed to purchase an additional $1 million in two tranches by September 5, 2023 ("Initial Funding").
- Debt Maturity Extension: Maturity dates for existing promissory notes with Maxim Group LLC, LM Funding America, Inc., and LMFAO Sponsor, LLC extended to 91 days after the last maturity date of the new Notes.
Material Changes Versus Prior Period
The filing reports material amendments to the March 15, 2023, Securities Purchase Agreement (SPA) and Registration Rights Agreement (RRA):
- Discretionary Purchasing: The Purchaser now has discretion to purchase up to $2 million in aggregate principal amount (including Initial Funding) after the Second Closing Date.
- Payment Waiver: A 6-month waiver period was granted for cash payment obligations (installments and interest) on existing and future Notes.
- Prepayment Waiver: Lenders waived rights to mandatory prepayments from proceeds of the Convertible Note Financing.
- Registration Timeline: The Company must file a resale registration statement within 15 calendar days of the Purchaser's request, commencing 91 days after the RRA Amendment effective date.
Guidance, Outlook, Risks, and Contingencies
Management Commentary: The Company is actively restructuring its financing terms to secure liquidity and extend maturity dates while managing cash outflows through payment waivers.
Risks and Contingencies:
- Liquidated Damages: Failure to meet obligations under the Registration Rights Agreement may trigger liquidated damages payments.
- Dilution: Significant potential dilution exists due to the issuance of warrants covering over 5.5 million shares and the low conversion price ($0.20) of the convertible notes.
- Compliance: The Company must adhere to strict timelines for filing resale registration statements to avoid penalties.
Unusual Items: The filing does not disclose unusual items outside of the specific debt restructuring and waiver agreements described above.
Investor Verification Checklist
- Verify the exact effective date of the RRA Amendment to calculate the 91-day window for filing the resale registration statement.
- Confirm the total outstanding principal amount of all convertible notes and promissory notes post-amendment.
- Review the full text of the Letter Agreement (Exhibit 10.3) for specific details on the conversion price adjustment mechanisms.
- Monitor the September 5, 2023, deadline for the $1 million "Initial Funding" tranche.
- Assess the impact of the 6-month payment waiver on the Company's immediate cash flow requirements versus long-term debt obligations.